

Notice of Allowability	Application No.	Applicant(s)	
	10/625,934	SETCHELL ET AL.	
	Examiner	Art Unit	
	SUSANNAH CHUNG	1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 3/12/08.
2. The allowed claim(s) is/are 1,4,5,44 and 54.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date 20080506.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

DETAILED ACTION

Claims 1, 2, 4-5, 12-19, 44-45, and 51-55 are pending in the instant application. Claims 3, 6-11, 10-43, and 46-50 are canceled.

Response

Applicant's Rule 132 declaration, remarks and amendment to the claims filed on 3/12/08 are acknowledged. The rejections made in the previous office action are withdrawn in view of the amendment to the claims, declaration and response.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 7/25/2006 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Attorney Patrick Skacel on 05/06/08.

The application has been amended as follows:

Delete claims 2, 12-19, 45, 51-53 and 55.

In claim 1, page 2 of 13, line 2, **insert** ---and a pharmaceutically acceptable adjuvant, carrier or excipient--- after the word (s-equol).

In claim 4, page 2 of 13, line 1, **insert** ---pharmaceutical--- before the word composition.

In claim 4, page 2 of 13, line 1, **delete** "isolated" before the word s-equol.

In claim 5, page 2 of 13, line 1, **insert** ---pharmaceutical--- before the word composition.

In claim 44, page 4 of 13, line 1, **insert** ---pharmaceutical--- before the word composition.

In claim 44, page 4 of 13, line 1, **insert** ---further--- after the word is.

In claim 54, page 5 of 13, line 2, **insert** ---and a pharmaceutically acceptable adjuvant, carrier or excipient--- after the word agent.

Reasons for Allowance

The present invention is directed to pharmaceutical compositions comprising the S enantiomer of equol. The closest prior art of record is U.S. Pat. No. 6,455,032 (Kelly et al.), which teaches equol, but does not teach or provide the requisite motivation to make the instantly claimed pharmaceutical compositions wherein the composition consists mainly of S-equol for pharmaceutical use. The instant specification teaches the method of making the instantly claimed S-equol (see page 15) and teaches that these compounds have unexpected pharmaceutical utility (see pages 1-8), wherein the S-equol compositions differ from other

isoflavones in that they may actually inhibit the development of breast and prostate cancer (see bioavailability data on pages 37-42).

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susannah Chung whose telephone number is (571) 272-6098. The examiner can normally be reached on M-F, 8am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/REI-TSANG SHIAO /
Primary Examiner, Art Unit 1626

Susannah Chung, 5/6/2008